Denali Therapeutics (DNLI) Stock Forecast & Price Target

$25.05 -3.40 (-11.95%)

(As of 11/15/2024 ET)

Denali Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 11 Analyst Ratings

Sell
0

Hold
3

Buy
8

Based on 11 Wall Street analysts who have issued ratings for Denali Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 3 have given a hold rating, and 8 have given a buy rating for DNLI.

Consensus Price Target

$38.90
55.29% Upside

According to the 11 analysts' twelve-month price targets for Denali Therapeutics, the average price target is $38.90. The highest price target for DNLI is $90.00, while the lowest price target for DNLI is $22.00. The average price target represents a forecasted upside of 55.29% from the current price of $25.05.

Get the Latest News and Ratings for DNLI and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Denali Therapeutics and its competitors.

DNLI Analyst Ratings Over Time

Type	Current Forecast 11/18/23 to 11/17/24	1 Month Ago 10/19/23 to 10/18/24	3 Months Ago 8/20/23 to 8/19/24	1 Year Ago 11/18/22 to 11/18/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	7 Buy rating(s)	8 Buy rating(s)	11 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$38.90	$38.22	$39.33	$52.20
Forecasted Upside	55.29% Upside	38.54% Upside	64.23% Upside	178.25% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

2024's Must-Watch Stocks! (Ad)

Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.

[Unlock Your Report Now]

DNLI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DNLI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Denali Therapeutics Stock vs. The Competition

Type	Denali Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.73	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	55.29% Upside	28,534.42% Upside	9.87% Upside
News Sentiment Rating	Neutral News See Recent DNLI News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/7/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$90.00 ➝ $90.00	+204.57%
11/1/2024	Jefferies Financial Group 2 of 5 stars		Boost Target	Buy ➝ Buy	$40.00 ➝ $45.00	+64.65%
10/11/2024	JPMorgan Chase & Co. 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$29.00 ➝ $28.00	+6.99%
10/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
10/7/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Schimmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
9/4/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$25.00 ➝ $29.00	+15.45%
Get the Latest News and Ratings for DNLI and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
8/2/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$26.00 ➝ $32.00	+49.18%
8/2/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$30.00 ➝ $26.00	+18.94%
5/8/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$26.00 ➝ $22.00	+13.99%
4/9/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$70.00 ➝ $32.00	+65.29%
2/29/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$73.00 ➝ $50.00	+142.01%
9/6/2023	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$38.00	+59.40%
4/12/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$61.00 ➝ $63.00	+164.26%
3/2/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$85.00 ➝ $70.00	+156.41%
2/28/2023	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$80.00 ➝ $50.00	+84.16%
1/30/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Goodman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00	+63.83%
1/30/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$50.00	+58.88%
12/5/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 06:34 AM ET.

DNLI Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Denali Therapeutics is $38.90, with a high forecast of $90.00 and a low forecast of $22.00.
: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DNLI shares.
: According to analysts, Denali Therapeutics's stock has a predicted upside of 55.29% based on their 12-month stock forecasts.
: Over the previous 90 days, Denali Therapeutics's stock had 1 downgrade by analysts.
: Denali Therapeutics has been rated by research analysts at Bank of America, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group, JPMorgan Chase & Co., and Raymond James in the past 90 days.
: Analysts like Denali Therapeutics less than other "medical" companies. The consensus rating score for Denali Therapeutics is 2.73 while the average consensus rating score for "medical" companies is 2.80. Learn more on how DNLI compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Why buying gold might be a mistake (Ad)

Something strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level.

If you're interested, check out the recording here while the link's still up.

This page (NASDAQ:DNLI) was last updated on 11/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Denali Therapeutics (DNLI) Stock Forecast & Price Target